Bristol-Myers Squibb (NYSE: BMY ) is one of the globe's top drugmakers and a staple in dividend investors' portfolios.
Big drug companies such as Bristol-Myers, Johnson & Johnson (NYSE: JNJ ) , and Merck (NYSE: MRK ) offer investors predictable, dividend-boosting revenue regardless of the economy's whims and whispers. But investors are correct to wonder if Bristol-Myers' dividend can be sustained following the loss of patent protection on the company's top-selling drug Plavix two years ago and in light of billions more in at-risk revenue tied to future patent expirations.
In the following slideshow you'll see whether I think Bristol's dividend is safe and gain insight into how Bristol-Myers matches up with industry peers.
Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.